CVS Health (NYSE: CVS) reported Q2 EPS of $1.83, $0.10 better than the analyst estimate of $1.73. Revenue for the quarter came in at $91.2 billion versus the consensus estimate of $91.43 billion.

GUIDANCE:

CVS Health sees FY2024 EPS of $6.40-$6.65, versus the consensus of $6.97.

For earnings history and earnings-related data on CVS Health (CVS) click here.